Ollie's Bargain Outlet 주식 (NASDAQ: OLLI)

Ollie's Bargain Outlet (NASDAQ:OLLI) 주식

OLLIE'S BARGAIN OUTLET HOLDI

Ollie's Bargain Outlet

Ollie's Bargain Outlet Holdings Inc is a retailer of closeout merchandise and excess inventory. The company sells name brand household related items that consumers use in their everyday lives at prices that are heavily discounted below traditional retailers. It offers customers a broad selection of brand name products, including housewares, bed and bath, food, floor coverings, health and beauty aids, books and stationery, toys, and electronics. It operates stores across the Eastern half of the United States. Its differentiated go-to-market plan is characterized by a fun and engaging treasure hunt shopping experience, compelling customer value proposition, and witty, humorous in-store signage and advertising campaigns.

Kuala,Lumpur,,Malaysia,-,December,01,,2023:,Interior,Shot,Of

Analyst Color

News

Price Target

Reiteration

Analyst Ratings

General

BBWI

BIRK

BOOT

BURL

LEVI

LULU

OLLI

ROST

URBN

JP모건 애널리스트 매튜 보스(Matthew R. Boss)에 따르면, 1분기 소매업 펀더멘털은 예상에 근접한 추세를 보이고 있으며, 부활절이 있는 4월 말에 더 강력한 모멘텀이 나타날 조짐을 보이고 있다. 

JP모건 애널리스트 &#34;관세 압력 증가 시 소비자들은 할인 소매업체 찾을 것&#34;

Recession,Proof,Is,Shown,Using,A,Text

Large Cap

Mid Cap

Opinion

Federal Reserve

Trading Ideas

이러한 불안정한 상황으로 인해 미국 증시가 글로벌 시장에 뒤처지면서 투자자들은 불안에 떨고 있다. 경기침체가 임박했다고 말하기에는 아직 이르지만, 방어적으로 생각하기에는 좋은 시기이다.

경기침체를 방어할 수 있는 주식 5종목

Shopping.Thanksgiving.BlackFriday.Shutterstock

FIVE

크리스마스 직전 토요일(&#39;슈퍼 새터데이&#39;)인 12월 21일에는 소매업체의 오프라인 매장 방문을 의미하는 &#39;풋 트래픽&#39;이 급증했다. 홀리데이 쇼핑의 마지막 주에 수혜를 입은 종목을 살펴보자.

美 슈퍼 새터데이에 풋 트래픽 급증, 소매업체에 호재?

Ollie's Bargain Outlet Holdings, Inc. - Common Stock

Ollie's Bargain Outlet Holdings Inc

Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) is looking for Q2 Adj EPS of $0.32-$0.33 vs $0.30 analyst estimate. sees sales of $170.000 million-$175.000 million vs $160.29 million analyst estimate.

Guidance

ALAB

Astera Labs Sees Q2 Adj EPS $0.32-$0.33 vs $0.30 Est; Sees Sales $170.000M-$175.000M vs $160.29M Est

Safehold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAFE#NYSE">SAFE</a>) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0.42 by 4.76 percent. This is a 2.33 percent increase over earnings of $0.43 per share from the same period last year. The company reported quarterly sales of $97.70 million which beat the analyst consensus estimate of $96.06 million by 1.71 percent. This is a 4.81 percent increase over sales of $93.21 million the same period last year.

Earnings

Earnings Beats

SAFE

Safehold Q1 Adj. EPS $0.44 Beats $0.42 Estimate, Sales $97.70M Beat $96.06M Estimate

AMTM

Amentum Holdings Q2 Adj. EPS $0.53 Beats $0.47 Estimate, Sales $3.49B Beat $3.43B Estimate

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.09 by 600 percent. This is a 226 percent increase over losses of $(0.50) per share from the same period last year. The company reported quarterly sales of $53.30 million which beat the analyst consensus estimate of $43.87 million by 21.50 percent. This is a 80.47 percent increase over sales of $29.53 million the same period last year.

RIGL

Rigel Pharmaceuticals Q1 EPS $0.63 Beats $0.09 Estimate, Sales $53.30M Beat $43.87M Estimate

iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) reported quarterly losses of $(1.95) per share which missed the analyst consensus estimate of $(1.27) by 53.54 percent. This is a 27.45 percent decrease over losses of $(1.53) per share from the same period last year. The company reported quarterly sales of $101.57 million which missed the analyst consensus estimate of $125.00 million by 18.74 percent. This is a 32.29 percent decrease over sales of $150.01 million the same period last year.

Earnings Misses

IRBT

iRobot Q1 Adj. EPS $(1.95) Misses $(1.27) Estimate, Sales $101.57M Miss $125.00M Estimate

Opendoor Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPEN#NASDAQ">OPEN</a>) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.10) by 10 percent. This is a 25 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $1.15 billion which beat the analyst consensus estimate of $1.06 billion by 8.88 percent. This is a 2.37 percent decrease over sales of $1.18 billion the same period last year.

OPEN

Opendoor Technologies Q1 Adj. EPS $(0.09) Beats $(0.10) Estimate, Sales $1.15B Beat $1.06B Estimate

Option Care Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPCH#NASDAQ">OPCH</a>) has outperformed the market over the past 5 years by 7.99% on an annualized basis producing an average annual return of 21.81%. Currently, Option Care Health has a market capitalization of $5.35 billion. 
Buying $100 In OPCH: If an investor had bought $100 of OPCH stock 5 years ago, it would be worth $245.06 today based on a price of $32.66 for OPCH at the time of writing.
<h3>Option Care Health's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746563422_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OPCH

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) reported its first-quarter earnings on Monday. The following are comments from different analysts about the company&#8217;s performance.
BofA analyst John Murphy reiterated a Buy rating on the shares with a price forecast of $14.00.
Ford reported a first-quarter 2025 adjusted EPS of $0.14, surpassing both their own estimate of ($0.05) and the Bloomberg consensus of ($0.04). 
Adjusted EBIT was $1.0 billion, exceeding the forecast of $0.03 billion. Strong performance from Ford Blue and Model E drove the beat, while Ford Credit exceeded expectations, and Ford Pro fell short. 
EBIT was impacted by ~$200 million in tariff costs. Following the results and tariff impacts, the 2025 estimates have been lowered, while 2026 and 2027 estimates remain mostly unchanged, said the analyst.
Ford has suspended its guidance despite reporting strong business performance. It cites supply chain disruptions, tariff uncertainties, potential retaliatory actions, and policy changes regarding emissions regulations as the reasons.
Also Read: <a href="https://www.benzinga.com/25/05/45231071/whats-going-on-with-ev-maker-rivian-stock-today">What&#8217;s Going On With EV Maker Rivian Stock On Tuesday?</a>
The company estimates a gross tariff cost of $2.5 billion for FY25, with a net EBIT impact of approximately $1.5 billion, expecting to offset 40% of the tariff costs. 
Despite these challenges, Ford&#8217;s strong truck market position and large U.S. manufacturing footprint leave the company well-positioned to gain market share, opined the analyst.
Goldman Sachs analyst Mark Delaney reiterated a Neutral rating on the shares and raised the price forecast from $9.00 to $10.00.
Ford reported first-quarter revenue of $40.7 billion and adjusted EPS of $0.14, surpassing expectations. However, the company suspended its 2025 guidance due to uncertainties surrounding tariffs, policy and industry dynamics.
Ford estimates a $2.5 billion gross tariff exposure, with a net EBIT impact of $1.5 billion. Despite this, the company remains positive about its strong U.S. market position and long-term cost reduction potential. 
However, the analyst said challenges from international competition and a premium valuation lead to a maintained Neutral rating on the stock.
Price Action: Ford shares traded higher by 2.56% at $10.43 at last check on Tuesday.
Read Next: <a href="https://www.benzinga.com/25/05/45194848/footwear-giant-skechers-to-go-private-in-more-than-9b-deal-with-3g-capital-stock-surges">Footwear Giant Skechers To Go Private At 30% Premium In PE Deal</a>
Photo: Shutterstock

Ford Outperforms In Q1, Faces Tariff Challenges Ahead, Say Analysts

Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) raises FY2025 sales outlook from $390.00 million-$410.00 million to $400.00 million-$420.00 million vs $399.07 million estimate.

PRCH

Porch Group Raises FY2025 Sales Guidance from $390.00M-$410.00M to $400.00M-$420.00M vs $399.07M Est

<h3>GAINERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/BBRRF">Blueberries Medical</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BBRRF#OTC">BBRRF</a>) shares closed up 21.95% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/FFNTF">4Front Ventures</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFNTF#OTC">FFNTF</a>) shares closed up 18.67% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/TGIFF">1933 Industries</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TGIFF#OTC">TGIFF</a>) shares closed up 13.40% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/OGI">Organigram Global</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OGI#NASDAQ">OGI</a>) shares closed up 6.26% at $1.10</li>
<li><a href="https://www.benzinga.com/quote/CURR">Currenc Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURR#NASDAQ">CURR</a>) shares closed up 4.89% at $1.27</li>
<li><a href="https://www.benzinga.com/quote/LBUY">Leafbuyer Techs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LBUY#OTC">LBUY</a>) shares closed up 4.88% at $0.02</li>
<li><a href="https://www.benzinga.com/quote/NWVCF">EnWave</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NWVCF#OTC">NWVCF</a>) shares closed up 3.89% at $0.22</li>
<li><a href="https://www.benzinga.com/quote/CWBHF">Charlottes Web Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CWBHF#OTC">CWBHF</a>) shares closed up 3.41% at $0.09</li>
<li><a href="https://www.benzinga.com/quote/CBWTF">Auxly Cannabis Group</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBWTF#OTC">CBWTF</a>) shares closed up 3.33% at $0.06</li>
</ul>
<h3>LOSERS:</h3>
<ul>
<li><a href="https://www.benzinga.com/quote/YCBD">cbdMD</a> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) shares closed down 28.86% at $0.13</li>
<li><a href="https://www.benzinga.com/quote/RMHB">Rocky Mountain High</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RMHB#OTC">RMHB</a>) shares closed down 18.03% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/CRBP">Corbus Pharmaceuticals</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) shares closed down 11.59% at $6.25</li>
<li><a href="https://www.benzinga.com/quote/CNBX">CNBX Pharmaceuticals</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNBX#OTC">CNBX</a>) shares closed down 11.11% at $0.00</li>
<li><a href="https://www.benzinga.com/quote/SOLCF">SOL Global Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SOLCF#OTC">SOLCF</a>) shares closed down 9.01% at $0.08</li>
<li><a href="https://www.benzinga.com/quote/OILFF">Nextleaf Solutions</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OILFF#OTC">OILFF</a>) shares closed down 7.91% at $0.04</li>
<li><a href="https://www.benzinga.com/quote/CNTMF">FLUENT</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) shares closed down 6.70% at $0.05</li>
<li><a href="https://www.benzinga.com/quote/CURLF">Curaleaf Holdings</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) shares closed down 6.33% at $0.87</li>
<li><a href="https://www.benzinga.com/quote/GTBIF">Green Thumb Indus</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>) shares closed down 5.76% at $6.05</li>
<li><a href="https://www.benzinga.com/quote/XXII">22nd Century Group</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>) shares closed down 4.91% at $1.19</li>
<li><a href="https://www.benzinga.com/quote/GNLN">Greenlane Hldgs</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLN#NASDAQ">GNLN</a>) shares closed down 4.69% at $0.01</li>
<li><a href="https://www.benzinga.com/quote/ZDPY">Zoned Properties</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ZDPY#OTC">ZDPY</a>) shares closed down 4.55% at $0.42</li>
<li><a href="https://www.benzinga.com/quote/CLSH">CLS Holdings USA</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CLSH#OTC">CLSH</a>) shares closed down 4.29% at $0.03</li>
<li><a href="https://www.benzinga.com/quote/TCNNF">Trulieve Cannabis</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TCNNF#OTC">TCNNF</a>) shares closed down 4.28% at $4.47</li>
<li><a href="https://www.benzinga.com/quote/TLRY">Tilray Brands</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) shares closed down 3.94% at $0.42</li>
<li><a href="https://www.benzinga.com/quote/CRLBF">Cresco Labs</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) shares closed down 3.86% at $0.86</li>
<li><a href="https://www.benzinga.com/quote/CXXIF">C21 Investments</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CXXIF#OTC">CXXIF</a>) shares closed down 3.66% at $0.16</li>
<li><a href="https://www.benzinga.com/quote/GRWG">GrowGeneration</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRWG#NASDAQ">GRWG</a>) shares closed down 3.45% at $1.12</li>
<li><a href="https://www.benzinga.com/quote/IIPR">Innovative Ind Props</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) shares closed down 3.16% at $53.00</li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cannabis

Markets

Movers

BBRRF

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CLSH

CNBX

CNTMF

CRBP

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

CWBHF

CXXIF

FFNTF

GNLN

GRWG

GTBIF

IIPR

LEAFBUYER TECHNOLOGIES by Leafbuyer Technologies, Inc.

LBUY

NWVCF

OILFF

RMHB

SOLCF

TCNNF

TGIFF

TLRY

XXII

YCBD

ZDPY

Cannabis Stock Gainers And Losers From May 6, 2025

Porch Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCH#NASDAQ">PRCH</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.12) by 166.67 percent. This is a 138.1 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $104.75 million which beat the analyst consensus estimate of $79.44 million by 31.86 percent. This is a 9.27 percent decrease over sales of $115.44 million the same period last year.

Porch Group Q1 EPS $0.08 Beats $(0.12) Estimate, Sales $104.75M Beat $79.44M Estimate

Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) raises FY2025 sales outlook from $675.50 million-$680.50 million to $691.00 million-$695.00 million vs $676.04 million estimate.

JAMF

Jamf Holding Raises FY2025 Sales Guidance from $675.50M-$680.50M to $691.00M-$695.00M vs $676.04M Est

Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.28 by 17.86 percent. This is a 230 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $159.44 million which beat the analyst consensus estimate of $153.13 million by 4.12 percent. This is a 144.33 percent increase over sales of $65.26 million the same period last year.

Astera Labs Q1 Adj. EPS $0.33 Beats $0.28 Estimate, Sales $159.44M Beat $153.13M Estimate

comScore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>) narrows FY2025 sales outlook from $360.00 million-$370.00 million to $360.00 million vs $378.80 million estimate.

SCOR

comScore Narrows FY2025 Sales Guidance from $360.00M-$370.00M to $360.00M vs $378.80M Est

Jamf Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAMF#NASDAQ">JAMF</a>) sees Q2 sales of $167.500 million-$169.500 million vs $165.78 million analyst estimate.

Jamf Holding Sees Q2 Sales $167.500M-$169.500M vs $165.78M Est

WIIM

CPIX

Cumberland Pharmaceuticals shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) reported quarterly earnings of $0.57 per share. This is a 17.39 percent decrease over earnings of $0.69 per share from the same period last year. The company reported $68.03 million in sales this quarter. This is a 4.93 percent decrease over sales of $71.56 million the same period last year.

WEYS

Weyco Group Q1 EPS $0.57 Down From $0.69 YoY, Sales $68.03M Down From $71.56M YoY

Groundbreaking solution simplifies AI inferencing for specialized and local applications
NetApp&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>), the intelligent data infrastructure company, today announced the release of NetApp AIPod Mini with Intel, a joint solution designed to streamline enterprise adoption of AI inferencing. This collaboration addresses the unique challenges businesses face when deploying AI, such as cost and complexity, at the department and team level.
To thrive in the era of intelligence, enterprises have adopted AI to enhance efficiency and data-driven decision making across their businesses. A <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fmitsloan.mit.edu%2Fsites%2Fdefault%2Ffiles%2F2023-10%2FSSRN-id4573321.pdf&amp;esheet=54249584&amp;newsitemid=20250506422545&amp;lan=en-US&amp;anchor=study+by+Harvard+Business+School&amp;index=1&amp;md5=bfad42d72cefd6a6e06f70ec4c5d507e">study by Harvard Business School</a> found that consultants given access to AI tools were able to increase their productivity, completing 12.2 percent more tasks and completing them 25.1 percent more quickly. However, individual business units may find that the broadly available general purpose AI applications are not able to meet their specific needs, but do not have the technical expertise or budget to customize an AI application from scratch. NetApp and Intel have partnered to provide businesses with an integrated AI inferencing solution built on an intelligent data infrastructure framework that allows specific business functions to leverage their distinct data to create outcomes that support their needs. NetApp AIPod Mini streamlines the deployment and use of AI for specific applications such as automating aspects of document drafting and research for legal teams, implementing personalized shopping experiences and dynamic pricing for retail teams, and optimizing predictive maintenance and supply chains for manufacturing units.
"Our mission is to unlock AI for every team at every level without the traditional barriers of complexity or cost," said Dallas Olson, Chief Commercial Officer at NetApp. "NetApp AIPod Mini with Intel gives our customers a solution that not only transforms how teams can use AI but also makes it easy to customize, deploy, and maintain. We are turning proprietary enterprise data into powerful business outcomes."

Contracts

INTC

NTAP

NetApp And Intel Enter Partnership For AI for Enterprises

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) reported lower-than-expected first-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45206073/vertex-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">quarter 2025 earnings</a>.
Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $4.32</a>.
The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion.
Total revenue&nbsp;increased by 3%, primarily driven by the continued performance of Trikafta/Kaftrio&nbsp;and an early contribution from the&nbsp;U.S.&nbsp;launch of Alyftrek.
<ul>
<li>In the U.S., total revenue increased 9% to $1.66 billion due to continued strong patient demand and higher net realized pricing.</li>
<li>Outside the U.S., total revenue decreased 5% to $1.11 billion, as strong patient demand in established and newer markets was offset by the expected revenue decline in Russia, where Vertex is experiencing a violation of its intellectual property rights. </li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44569612/vertex-discontinues-development-of-type-1-diabetes-candidate-after-disappointing-data" rel="noreferrer noopener">Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data</a>
&#8220;Vertex delivered a strong start to 2025 with notable execution across the business as we grow and diversify the revenue base, progress multiple launches and advance the R&amp;D pipeline. We continued to expand our leadership in CF and build global momentum for CASGEVY, and we launched JOURNAVX in moderate-to-severe acute pain,&#8221; said&nbsp;Reshma Kewalramani, CEO and President of&nbsp;Vertex. &#8220;With multiple programs in pivotal development including povetacicept, which continues to make rapid progress in achieving its potential as a pipeline-in-a-product, and additional programs in early and mid-stage development,&nbsp;Vertex&nbsp;is poised to continue to deliver value for years to come.&#8221;
Guidance: Vertex raised the low end of total revenue guidance by&nbsp;$100 million&nbsp;to&nbsp;$11.85&nbsp;billion-$12 billion from $11.75 billion-$12 billion, compared to the consensus of $11.97 billion.
The guidance also includes an immaterial cost impact from tariffs in 2025 based on currently known tariff rates and regulations.
Vertex&nbsp;has temporarily paused the multiple ascending dose portion of the Phase 1/2 study of VX-522, a nebulized CFTR mRNA therapy, to assess a tolerability issue.
William Blair writes, &#8220;While the pause is unfortunate, we believe that the decision to pause the study rather than discontinue it suggests that, beyond the tolerability issue, management is encouraged by the data generated to date given it is open-label.&#8221;
Analyst Myles Minter writes, &#8220;While there was a slight miss on the top line leading to shares trading off 3% in the aftermarket, management raised the lower end of total revenue guidance, suggesting Street estimates may not have fully encompassed the previously disclosed impacts of an unauthorized Trikafta copy in Russia. We would be buyers on weakness here as the CF franchise still represents one of the most stable long-term growth franchises with a competitive moat in the biotech sector.&#8221;
Analyst reactions:
<ul>
<li>Leerink Partners downgrades Vertex from Outperform to Market Perform and lowers the <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $550 to $503</a>.</li>
<li>Needham reiterates Vertex Pharmaceuticals from Hold to Hold.</li>
<li>JP Morgan maintains Vertex with an Overweight rating, raising the price target from $512 to $515.</li>
</ul>
Price Action: VRTX stock closed lower by 9.91% at $450.61&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

VRTX

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

CURI

CuriosityStream shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance above estimates.

Press Releases

Ollie's Bargain Outlet Holdings, Inc. Announces Third Quarter Fiscal 2024 Release Date and Conference Call Information

Ollie's Bargain Outlet Holdings, Inc. Reports Third Quarter Fiscal 2024 Financial Results

OLLIE'S RAISES OVER $1.1 MILLION FOR MARINE TOYS FOR TOTS PROGRAM

Management

Ollie's Bargain Outlet Announces the Appointment of Eric van der Valk to President & Chief Executive Officer, Completing Leadership Succession Plan

OLLIE'S CELEBRATES THE  GRAND OPENING OF FOUR WISCONSIN STORES

Ollie's Bargain Outlet Acquires 40 Former Big Lots Stores from Gordon Brothers

Ollie's Bargain Outlet Announces Fourth Quarter and Full-Year Fiscal 2024 Earnings Release Date and Conference Call Information

Ollie's Bargain Outlet Holdings, Inc. Reports Fourth Quarter and Fiscal 2024 Financial Results

Ollie's Bargain Outlet Holdings, Inc. Announces New $300 Million Share Repurchase Authorization

OLLIE'S RAISES OVER $830,000 FOR FEEDING AMERICA®

Amazon.com

Alibaba Group Holding Limited American Depositary Shares each representing eight Ordinary share

Alibaba Gr Hldgs

Baozun

Coupang

Dillard's

1stdibs.com

eBay

Etsy

Global E Online

Groupon

D-Market Electronic Services & Trading - American Depositary Shares

D-MARKET Electronic

Hour Loop

JD.com, Inc. - American Depositary Shares

JD.com

Jumia Technologies AG American Depositary Shares, each representing two Ordinary Shares

Jumia Technologies

Nordstrom

Kohl's

ContextLogic

Macy's

MercadoLibre

MINISO Group Holding Limited American Depositary Shares, each representing four Ordinary Shares

MINISO Group Holding

PDD Holdings Inc. - American Depositary Shares

PDD Holdings

QVC Group

Savers Value Village

Vipshop Holdings Limited American Depositary Shares, each representing two ordinary shares

Comments

Ollie's Bargain Outlet

뉴스

파트너 / 기고자

벤징가 글로벌